• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

AstraZeneca-Daiichi Sankyo’s therapy shows response in breast cancer trials

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Dec 12, 2022 at 10:52: AM
via AstraZeneca and Daiichi Sankyo have reported updated data from the Phase I TROPION-PanTumor01 clinical trial, where their datopotamab deruxtecan (Dato-DXd) showed to offer encouraging responses in heavily pretreated metastatic triple-negative breast cancer (TNBC) patients.

article source
 

<



Similar threads

cafead
AstraZeneca and Daiichi Sankyo’s Enhertu shows promise in breast cancer trial
Replies
0
Views
61
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Daiichi Sankyo and AstraZeneca’s lung cancer antibody set for FDA review
Replies
0
Views
130
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Daiichi Sankyo again dials up Enhertu sales forecast, advances 2nd AstraZeneca-partnered ADC
Replies
0
Views
118
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
AstraZeneca, Daiichi Sankyo show off ADC portfolio with safety top of mind
Replies
0
Views
176
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
AstraZeneca, Daiichi Sankyo tease new Enhertu data — but details remain under wraps
Replies
0
Views
296
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote